I obtained PhD in Pharmacy at the University of the Basque Country UPV/EHU in 2022. During my Thesis studies and thereafter I have focused my scientific career in the study of brain endocannabinoid endocannabinoid system. I initially combined biochemical and radioligand binding methods to investigate the expression and/coupling ability of cannabinoid CB1 receptors in rodent and human brain. Following a first post-doctoral period at Neurocentre Magendie, in which I acquired expertise in electrophysiology in brain slices and endocannabinoid-mediated synaptic plasticity mechanisms (Mato et al. Nat Neurocience 2004; Mato et al. J Neuroscience 2005), I started over a 3 year post-doctoral stay at the UPV/EHU aimed at gaining knowledge and training in calcium analysis and its application to the study of white matter diseases (Mato et al. Glia 2009, 2010). I was granted a RyC contract in 2008 and I hold a Permanent Research position at the UPV/EHU since 2017. My research activity focuses on the analysis of endocannabinoids as modulators of glial cell function in health and disease. In particular, a main research objective of my team is to evaluate the involvement of CB1 receptor populations located in glial cells – astrocytes, oligodendrocytes and microglia - in the bioenergetic processes that govern white matter biology and pathology and determine their usefulness as possible therapeutic targets in demyelinating disorders. To achieve these aims we use using electrophysiology, live imaging in vitro and ex vivo (confocal and 2-foton), rodent disease models and hiPSC technology.